Role of Tranexamic Acid (TXA) in the Reduction of Post-operative Hematoma and Seroma in Patients Undergoing Panniculectomy or Abdominoplasty, a Pilot Study.
Phase: PHASE4
Conditions: Panniculectomy, Abdominoplasty
Sponsor: The Reading Hospital and Medical Center

Reading Hospital – Tower Health 
 
Research Protocol   
     
 
 
 
 
 
 
Page 1 of 7 
 
PI Name:  Amir Behnam, M.D. 
 
Study Title:  Role of tranexamic acid (TXA) in the reduction of post-operative hematoma 
and seroma in patients undergoing panniculectomy or abdominoplasty, a pilot study 
 
NCT04902950 
February 27, 2020 
 
 
 

Reading Hospital – Tower Health 
 
Research Protocol   
     
 
 
 
 
 
 
Page 2 of 7 
 
PI Name:  Amir Behnam, M.D. 
 
Study Title:  Role of tranexamic acid (TXA) in the reduction of post-operative hematoma 
and seroma in patients undergoing panniculectomy or abdominoplasty, a pilot study  
 
Other Investigators / Collaborators Kayla Humenansky, D.O., Christine Cho, D.O., 
Thomas Dooley, M.D., Scott Lindsay, D.O., Roman Gokhman, PharmD. 
 
Funding Source(s): Investigators will apply for funding from the Reading Hospital Foundation. 
If funding from the foundation is unavailable, investigators will seek other funding sources. If no 
funding is acquired, the investigators will cover the cost of the study drug.  
 
A.SPECIFIC AIMS  
We aim to investigate the use of tranexamic acid (TXA) as a hemostatic agent in 
abdominoplasty/panniculectomy. We believe tranexamic acid to be effective in decreasing 
hematoma rates and drain output, allowing for earlier drain removal. 
 
B. RESEARCH QUESTION AND HYPOTHESIS  
Does the use of TXA soaked sponges decrease hematoma rates and drain output, resulting in 
earlier drain removal in patients undergoing panniculectomy or abdominoplasty? 
Comparative outcomes including return to operating room, fluid collection requiring additional 
procedures (i.e. aspiration or percutaneous drainage), hematoma rates, daily drain output and 
time to drain removal will be measured between the control group (normal saline) and the 
experimental group (TXA). We are evaluating the potential for TXA to reduce drain output and 
decrease time to drain removal.  
 
C. BACKGROUND AND SIGNIFICANCE 
The antifibrinolytic drug, tranexamic acid (TXA) has proven to reduce blood loss and transfusion 
requirements in other fields of surgery including orthopedic, cardiac, craniofacial and 
gynecologic surgery. Metanalysis performed by Ker et al. concluded that TXA reduced blood 
loss by 29 percent and the need for blood transfusion by 49 percent over a variety of surgical 
procedures.1 Masoomi et al. reviewed 20,130 patients who underwent abdominoplasty from 
2007-2011, noting that 9.3 percent required a post-operative blood transfusion.2 
 
TXA has recently gained popularity in the field of plastic and reconstructive surgery.3 
Tranexamic acid is a synthetic lysine analogue which inhibits fibrinolysis and thus degradation 
of fibrin clots by competitively inhibiting the activation of plasminogen to plasmin. By inhibiting 
plasmin formation, TXA also provides an anti-inflammatory effect, as plasmin is responsible for 
several inflammatory activities.3,4 Austen et al. demonstrated the efficacy of topical TXA in 
reducing drain output for patient undergoing reduction mammoplasty.5 
 
The safety and efficacy of TXA has been well studied.6 Historically administered intravenously, 
TXA is gaining popularity as a topical hemostatic agent. TXA administered topically has similar 
efficacy as intravenous administration while minimizing systemic exposure.6 The Clinical 
Randomization of an Antifibrinolytic in Significant Haemorrhage-2 trial (CRASH-2) found that the 
use of TXA provided a significant mortality benefit without an increased risk for thromboembolic 
events in adult trauma patients.  
 

Reading Hospital – Tower Health 
 
Research Protocol   
     
 
 
 
 
 
 
Page 3 of 7 
 
We believe topical TXA will decrease the rate of post-operative hematoma via its hemostatic 
effects, as well as decrease the overall drain output via its anti-inflammatory properties.  
 
D. RESEARCH DESIGN AND METHODS (including data analysis)  
 
Patients will be evaluated by the plastic surgeon for a symptomatic abdominal panniculus to 
determine their candidacy for elective or insurance authorized panniculectomy. Panniculectomy 
is defined as excision of excess lower abdominal skin and subcutaneous tissue. The term 
panniculectomy is often used interchangeably with abdominoplasty. Candidates for the study 
will be undergoing excision of excess abdominal skin and subcutaneous tissue with 
undermining of the abdominal flap to the xiphoid process superiorly and to the costal margin 
laterally; with or without rectus muscle plication. Signs and symptoms of a symptomatic 
abdominal panniculus include but are not limited to recurrent skin infections, difficulty with 
ambulation, interference with voiding or intercourse, as well as chronic lower back pain or 
difficulty finding appropriately fitting clothing.  
 
Participating providers will include those physicians with operative privileges at Tower Health 
System Reading Hospital. Candidates for the procedure will be offered participation in the study 
preoperatively in the office setting by the provider performing the procedure. If they agree to 
participate, they will be consented appropriately with the attached IRB approved consent in 
addition to standard surgical consent.  
 
This study will be double-blinded. Participating patients will be randomized to normal saline 
(control group) or tranexamic acid (study population) on the day of surgery by the pharmacist. 
All participants will have an order placed pre-operatively for tranexamic acid. Patient assignment 
will be determined by a random number table. A random number table is a series of digits 0, 1, 
2, 3, 4, 5, 6, 7, 8, and 9 arranged randomly in rows and columns. Numbers in the list are 
arranged so that each digit has no predictable relationship to the digits that preceded it or to 
the digits that followed it. Each group will have 10 participants. One for each number in the 
table. Odd numbers will be assigned to the control group (Saline) and even numbers will be 
assigned to the study population (TXA). The pharmacist will have the table of random numbers 
and will assign patients appropriately. The pharmacist will send a 100cc bag of plain normal 
saline or 100cc bag of normal saline mixed with 3g of tranexamic acid. Tranexamic acid is 
supplied as 1g/10cc. Three grams of TXA will be mixed with 70cc of normal saline for a 
concentration of 3% and total volume of 100cc, as not to differ from the plain normal saline 
quantity. Either 100cc of plain normal saline or 100cc of 3% solution of TXA will be placed on 
the operative field prior to the start of the procedure. The solution will be placed into a sterile 
bowl on the operative field and three lap sponges will be placed in the solution at the beginning 
of the procedure. TXA is clear, odorless solution and will be indistinguishable from normal saline 
to the provider and operating room staff. To ensure the study providers remain blinded the 
pharmacist will control the randomization. 
 
Each group will have 10 participants. Group 1 will undergo application of three normal saline 
soaked lap sponges to the surgical site, while Group 2 will undergo application of three TXA 
soaked lap sponges to the surgical site. After the abdominal skin and subcutaneous tissue is 
raised, the area will be irrigated, and hemostasis achieved using electrocautery. These steps 
are currently preformed with every panniculectomy. After hemostasis and irrigation, the soaked 
lap sponges will be unfolded and placed beneath the two lateral portions as well as the central 
area of the flap for 3 minutes. The lap sponges will not be “rung out” prior to placement. The 
time for TXA application is based on previous studies. The lap sponges will be removed after 

Reading Hospital – Tower Health 
 
Research Protocol   
     
 
 
 
 
 
 
Page 4 of 7 
 
three minutes. The surface area under the flap will be measured from the xiphoid process to the 
pubis, from the Xiphoid process to each anterior superior iliac spine (ASIS) and across from one 
ASIS to the other. These measurements will be used to calculate the surface area under the 
flap. These measurements will only be used in data collection and do not affect the principle aim 
of the study. The remainder of the surgical procedure will be the same for each patient. As 
currently practiced, two 15 round Blake drains will be placed for each patient. Patients will stay 
overnight for routine post-operative monitoring including vital signs and drain output or may be 
discharged home the same day of surgery if medically fit. Patients will also be monitored 
clinically at each post-operative visit for signs of post-operative hematoma or seroma.  
 
After discharge, post-operative drain output will be monitored and recorded by the patient on the 
provided drain documentation sheet. This does not differ from the current standard of care 
regarding drain output recordings. All patients who receive a post-surgical drain are asked to 
document output. All patients will be educated on routine drain care and recording drain output 
prior to surgery, as well as post-operatively. Each patient will be given a standardized form to 
record their drain output. Post-operative drain output will be assessed during each post-
operative visit. Drains will be removed when output is less than 30cc per drain in 24-hour period. 
Patients will track their 24-hour total drain output by recording the 24-hour total output at 10 am 
every day. If the output exceeds the drain capacity during the 24-hour interval but before the 
10am empty time, the patient will empty the drain when full, record that output, allow the drain 
output to reaccumulate, and empty-record the drain output again at 10am or again when the 
output exceeds the drain capacity.  The individual outputs recorded during the 24-hour interval 
will then be totaled to determine one output sum for the entire 24-hour time period between 
10am time intervals. Each drain bulb will accommodate a maximum of 60cc of postoperative 
fluid.  When less than 30 cc per drain in 24-hour period, patients will call to schedule drain 
removal. Drain recording policies do not differ from non-study patients. All post-operative 
panniculectomy patients are required to record their drain output. Each patient will be evaluated 
one week, three weeks, and eight weeks following their procedure to assess overall wound 
healing, post-operative fluid collections, drain output and overall well-being.   
 
Data analysis for this project will consist of several parts. First it is important to analyze 
differences between the randomized control and treatment arms to test for bias. In order to do 
this, goodness of fit tests (GOF) will be performed on demographic variables such as age and 
gender. While the sample sizes are expected to be low, 10 for each arm, nonparametric tests 
consisting of Fisher’s exact for discrete variables and Mann-Whitney U tests for continuous level 
data will be used. An omnibus p-value of 0.20 will be used to ensure there is no bias present in 
the samples. Secondly, efficacy analysis will be conducted on the outcome variables (drain 
output per day, total drain output, etc.) by use of Mann-Whitney U test. Statistically significant 
findings would be for a p-value less than 0.05 on any test. The samples are not expected to be 
large enough for the use of parametric measures so non-parametric methods will be used. 
 
With a small sample of 10 patients per arm this analysis is viewed to be exploratory, and there 
will be no statistical corrections applied for multiple comparisons. Results of the GOF and 
efficacy analysis will be prepared and placed into tables for each group. In addition to the 
analysis mentioned above, power analysis will also be used to calculate the observed power for 
those tests with significant differences as well as to determine a sample size for those efficacy 
endpoints that did not achieve statistical difference. These power estimates will accompany the 
results in a separate table. Power analysis will be based on single tail alternative hypothesis 
with a power (1-B) of 80 percent and a p-value of 0.05.  As this is an exploratory study, there will 

Reading Hospital – Tower Health 
 
Research Protocol   
     
 
 
 
 
 
 
Page 5 of 7 
 
be no interim analysis for efficacy or futility. The trial will be stopped after inclusion of twenty 
patients.   
 
E. PROTECTION OF HUMAN SUBJECTS 
1. RISKS TO THE SUBJECTS  
 
a. Human Subjects Involvement and Characteristics  
- 
Double-blind Prospective Randomized Control Trial 
- 
Female or male patients 18 years or older 
- 
Patients undergoing panniculectomy and agreeable to participate in the trial will 
be randomized to normal saline vs TXA 
- 
Daily drain output will be monitored and recorded for each patient 
- 
Rate of post-operative hematoma/seroma will be assessed by clinical evaluation 
to include palpation for ballotable fluid collection and assessment of skin for a 
shiny/tight appearance suggestive of an underlying fluid collection.  
- 
Prisoners, pregnant or nursing women, persons under the age of 18, persons 
with preexisting coagulopathy, ongoing venous or arterial thrombosis, history of 
cerebral vascular accident, uncontrolled seizure disorder, documented 
administration of daily antiplatelet or anticoagulation (e.g. ASA, NSAIDs, 
Warfarin) or documented allergic reaction to tranexamic acid will be excluded 
from the study 
- 
Patients can withdraw from the study at anytime 
 
b. Sources of Materials  
- 
All patient charts will be kept confidential, in compliance with HIPPA regulations 
- 
All patient information will be stored on a password protected computer 
- 
Normal saline and tranexamic acid are both products currently in use at the 
hospital in other plastic surgery procedures. They are indistinguishable in 
appearance, texture and odor; therefore, making them ideal substances for a 
double-blinded investigation   
- 
No specimens will be stored 
 
c. Potential Risks  
- 
Potential risks include those risks associated with any surgical procedure.  
- 
Patients will be monitored under standard operative protocols  
- 
Although, the risks of topical use of TXA are not well known, there are known 
risks from oral and intravenous use. Those risks include:  
o Allergic reaction 
o Convulsions have been reported in association with intravenous tranexamic 
acid treatment in patients undergoing cardiovascular procedures 
o Retinal changes have been documented in some animals receiving 
intravenous TXA for extended periods of time (days to weeks) 
o Intravenous administration of tranexamic acid may cause dizziness 
o Gastrointestinal disturbances may occur with intravenous administration 
 
2. ADEQUACY OF PROTECTION AGAINST RISKS  
 
a. Recruitment and Informed Consent 
- 
Female or male patients > 18 years for abdominal panniculectomy will be offered 
participation 

Reading Hospital – Tower Health 
 
Research Protocol   
     
 
 
 
 
 
 
Page 6 of 7 
 
- 
Consent will be obtained by the provider preforming the procedure  
- 
Signed and witnessed consent will be placed within the patient’s chart 
 
b. Protection against Risk 
- 
All patient charts will be kept confidential, in compliance with HIPPA regulations 
- 
All patient information will be stored on a password protected computer 
- 
All standard pre and post-operative photos will be stored on a password 
protected computer 
 
3. POTENTIAL BENEFITS OF THE PROPOSED RESEARCH TO THE SUBJECTS AND 
OTHERS  
- 
Our study aims to demonstrate a difference in hematoma rates as well as drain 
output between patients undergoing panniculectomy using topical tranexamic 
acid vs. normal saline. As a pilot study, these results could be used to encourage 
a larger investigation of the use of TXA in panniculectomy patients.  
 
4. IMPORTANCE OF THE KNOWLEDGE TO BE GAINED  
- 
This study allows us to investigate additional methods to achieve low drain 
outputs in panniculectomy. The knowledge gained from our proposed study will 
be applicable to patients undergoing panniculectomy. In addition, this method of 
achieving hemostasis may lead to further research studies for various other 
surgical procedures. 
 
5. SUBJECT SAFETY AND MINIMIZING RISKS (Data and Safety Monitoring Plan) 
 
Subject safety will be monitored by the physician preforming the procedure.  
- 
Subjects will be monitored for allergic reaction, wound healing complications, venous 
thromboembolism, drain output, and time to drain removal. 
- 
Subjects will be monitored during their overnight hospital stay, if overnight admission 
is deemed appropriate. Participants will also be evaluated at each follow-up visit. 
Patients will be scheduled for follow-up at one week, three weeks, and eight weeks 
following their procedure.  
- 
The physician performing the procedure will be responsible for the monitoring and 
evaluating patients postoperatively. 
- 
This investigational study aims to assess for any difference in drain output, time to 
drain removal or return to the OR for hematoma or seroma evacuation.   
 
F. REFERENCES/LITERATURE CITATIONS 
1. Ker K., Beecher D., and Roberts I. Topical application of tranexamic acid for the 
reduction of bleeding. The Cochrane database of systematic reviews 2013; 7.  
2. Masoomi H., Rimler J., Wirth G., et al. Frequency and risk factors of blood transfusion in 
abdominoplasty in post-bariatric surgery patients: data for the nationwide inpatient 
sample. Plast Reconstr Surg. 2015 May; 135(5): 861-868. 
3. Reed and Woolley. Uses of tranexamic acid. Continuing education in anaesthesia, 
Critical Care & Pain. 2015; 15(1):32-37. 
4. Jimenez J., Iribarren J., Lorente L, et al. Tranexamic acid attenuates inflammatory 
response in cardiopulmonary bypass surgery through blockade of fibrinolysis: a case 
control study followed by a randomized double-blind controlled trial. Critical Care 2007; 
11:R117. 

Reading Hospital – Tower Health 
 
Research Protocol   
     
 
 
 
 
 
 
Page 7 of 7 
 
5. Ausen K., Fossmark R., Spigset O., Pleym H. Randomized clinical trial of topical 
tranexamic acid after reduction mammoplasty. Br J Surg. 2015; 102:1348-1353.  
6. Rohrich RJ and Cho MJ. The role of tranexamic acid in plastic surgery: review and 
technical considerations. Plast Reconstr Surg. 2018 Feb; 141(2):507-515. 
 
G. CONSULTANTS 
Our statistician is a consultant for the hospital. 
 
H. FACILITES AVAILABLE 
Our trial will be conducted through Tower Health Reading Hospital Medical Center and its 
associates. 
 
I. INVESTIGATOR BROCHURE  
N/A   
 
J. APPENDIX 
Attach any additional information pertinent to the project such as: 
- 
surveys or questionnaires,  
- 
diaries or logs,  
- 
informed consent and/or HIPAA authorization documents, etc.